Last reviewed · How we verify
AOC 1044
AOC 1044 is an investigational antisense oligonucleotide.
AOC 1044 is an investigational antisense oligonucleotide. Used for Treatment of myasthenia gravis.
At a glance
| Generic name | AOC 1044 |
|---|---|
| Sponsor | Avidity Biosciences, Inc. |
| Drug class | antisense oligonucleotide |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
AOC 1044 targets and modulates the expression of a specific gene, leading to its therapeutic effects.
Approved indications
- Treatment of myasthenia gravis
Common side effects
- Injection site reaction
Key clinical trials
- Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping
- Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping (PHASE1, PHASE2)
- Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AOC 1044 CI brief — competitive landscape report
- AOC 1044 updates RSS · CI watch RSS
- Avidity Biosciences, Inc. portfolio CI